Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

Endocrine-Related Cancer - Tập 19 Số 5 - Trang 657-666 - 2012
Larry K. Kvols1, Kjell E. Öberg, Thomas M. O’Dorisio, Pharis Mohideen, Wouter W. de Herder, Rudolf Arnold, Ke Hu, Yilong Zhang, Gareth Hughes, Lowell Anthony, Bertram Wiedenmann
1H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA. [email protected]

Tóm tắt

Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and sst5. Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150 μg twice daily (bid), escalated to a maximum dose of 1200 μg bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600–900 μg s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600–900 μg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.

Từ khóa


Tài liệu tham khảo

Adams, 2004, Clinical endocrinology, 61, 431, 10.1111/j.1365-2265.2004.02098.x

Boerlin, 2003, Journal of endocrinological investigation, 26, 14

2009, Journal of Clinical Endocrinology & Metabolism, 94, 115, 10.1210/jc.2008-1008

Bruns, 1994, Annals of the New York Academy of Sciences, 733, 138, 10.1111/j.1749-6632.1994.tb17263.x

Bruns, 2002, European Journal of Endocrinology, 146, 707, 10.1530/eje.0.1460707

Fajans, 1989, Endocrinology and metabolism clinics of North America, 18, 45, 10.1016/S0889-8529(18)30388-8

Hofland, 2003, Endocrine Reviews, 24, 28, 10.1210/er.2000-0001

Lombardi, 2005, Journal of endocrinological investigation, 28, 36

Lattuada, 2007, Journal of neuroimmunology, 182, 153, 10.1016/j.jneuroim.2006.10.007

Li, 2004, The Journal of surgical research, 119, 130, 10.1016/j.jss.2004.03.006

Loftus, 1995, Advances in surgery, 28, 317

Long, 1981, BMJ, 282, 1767, 10.1136/bmj.282.6278.1767

2005, 128, 1717

2006, CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 4, 526, 10.1016/j.cgh.2005.12.008

Modlin, 2010, Alimentary pharmacology & therapeutics, 31, 169, 10.1111/j.1365-2036.2009.04174.x

2004, Annals of Oncology, 15, iv293, 10.1093/annonc/mdh942

ONO, 2007, Anticancer Research, 27, 2231

Pl  ckinger, 2004, Neuroendocrinology, 80, 394, 10.1159/000085237

2009, Journal of Clinical Oncology, 27, 4656, 10.1200/JCO.2009.22.8510

Ronga, 1995, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 39, 134

Rubin, 1999, Journal of Clinical Oncology, 17, 600, 10.1200/JCO.1999.17.2.600

2004, Neuroendocrinology, 80, 47, 10.1159/000080741

Therasse, 2000, JNCI Journal of the National Cancer Institute, 92, 205, 10.1093/jnci/92.3.205

Thông tin
Thông tin xuất bản

Endocrine-Related Cancer

Tập 19 Số 5

657-666

Thông tin tác giả